News | January 17, 2012

Tumor-Freezing Treatment Gives Ovarian Cancer Patients Extra Time

January 17, 2012 — Killing tumors by freezing them can add precious time to the lives of women with ovarian cancer that has spread to other parts of the body. Minimally invasive cryoablation extends lives and is cost-effective, according to a study being presented at the 4th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).

Once the cancer has spread (metastasized) beyond the ovaries, it is usually incurable, but surgery is often used to remove the tumors and extend life. Depending on the location of the tumors, however, that may not be an option, especially if the patient has previously undergone surgery to remove the cancer. The study shows cryoablation may be used to kill these tumors with extreme cold, resulting in significant survival time.

The study included 21 patients whose tumors in the abdomen, liver, lung and bone could not be removed surgically. Cryoablation was used to treat 48 tumors, killing 47 of them (98 percent). From the time of diagnosis of metastatic disease, average patient survival time was more than four years and seven months. That’s significant because women whose tumors are not successfully removed surgically – which occurs in about 60 percent of cases, according to studies – typically survive from about seven months to 2 years. On average, more than three years had transpired from the time of diagnosis to the first cryoablation treatment, meaning these women had already passed their expected survival time, and yet cryoablation was able to extend their survival even further. Some patients had multiple cryoablation treatments and of 41 procedures, there were three major complications (7 percent). The complications included two deaths that were attributed to the cancer, not to the procedure.

The study also determined the treatment extremely cost-effective, costing an average of $26,806 per life year saved, well below the current standard of $100,000.

Related Content

Philips Launches Azurion With FlexArm
Technology | Angiography | January 17, 2019
Philips announced the launch of Azurion with FlexArm, designed to enhance positioning flexibility for image-guided...
Videos | Interventional Radiology | January 11, 2019
Julius Chapiro, M.D., research faculty member and an...
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Podcast | Interventional Radiology | November 16, 2018
For the first time at the RSNA meeting, vendors of interventional products will have a dedicated area in which to dis
Feature | November 16, 2018 | By Greg Freiherr
For the first time at the RSNA meeting, vendors of interventiona
Body Vision Medical Announces Release of LungVision
Technology | Lung Cancer | October 05, 2018
Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its...
Image Diagnostics Debuting Interventional Radiation Shield at RSNA 2018
News | Radiation Dose Management | October 03, 2018
Image Diagnostics has entered into a product development agreement with ECLS Inc. to design a new radiation shield...
Image courtesy of Philips

Image courtesy of Philips

Feature | Interventional Radiology | July 05, 2018 | By Jeff Zagoudis
On May 14, 2018, First Lady Melania Trump underwent an embolization procedure for what was called a benign kidney...
Embolx Announces FDA Clearance of Next-generation Sniper Balloon Occlusion Microcatheter
Technology | Interventional Radiology | June 29, 2018
Embolx Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation...